Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders

Movement Disorders

Volumn 22, Issue 2, 2007, Pages 193-197

  Kenney, Christopher ^a   Hunter, Christine ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chorea; Tardive dyskinesia; Tetrabenazine; Tics; Tolerability

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; TETRABENAZINE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CHOREA; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERKINESIA; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; NAUSEA AND VOMITING; NERVOUSNESS; PARKINSONISM; PRIORITY JOURNAL; SALIVATION; SEX RATIO; SIDE EFFECT; TARDIVE DYSKINESIA; TIC; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGE OF ONSET; ANTI-DYSKINESIA AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; HUNTINGTON DISEASE; HYPERKINESIS; MALE; MIDDLE AGED; MYOCLONUS; PARKINSONIAN DISORDERS; PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TETRABENAZINE; TICS; TIME;

EID: 33847731495     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21222     Document Type: Article

References (46)

1. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-109.
2. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984;102:425-430.
3. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem 1986;47:331-339.
4. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-262.
5. Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, Fahn S. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983;225:515-521.
6. Pletscher A, Brossi A, Gey K. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int Rev Neurobiol 1962;4:275-306.
7. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362.
8. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25:300-302.
9. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27:230-233.
10. Frank S, Ondo W, Hunter C, et al. A randomized, double-blind, placebo-controlled, staggered withdrawal study in patients with Huntington's disease treated with tetrabenazine. Mov Disord 2005;20:1244.
11. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
12. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6:7-17.
13. Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington disease. Mov Disord 2006; DOI 10.1002/mds.21161.
14. Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985;46:19-24.
15. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-1281.
16. Tarsy D. Tardive dyskinesia. Curr Treat Options Neurol 2000;2:205-214.
17. Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984;34:688-692.
18. Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci 1987;14:541-546.
19. Jimenez-Jimenez FJ, Garcia-Ruiz PJ. Pharmacological options for the treatment of Tourette's disorder. Drugs 2001;61:2207-2220.
20. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214.
21. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1. Pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-547.
22. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2. Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714.
23. Ghaemi S, Hsu D, Rosenquist K, Pardo T, Goodwin F. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30;209-213.
24. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106.
25. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973;130:479-483.
26. Mikkelsen BO. Tolerance of tetrabenazine during long-term treatment. Acta Neurol Scand 1983;68:57-60.
27. Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine. Mov Disord 2006 (in press).
28. Kidd DW, McLellan DL. Self-poisoning with tetrabenazine. Br J Clin Pract 1972;26:179-180.
29. Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 1998;24:369-371.
30. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981;31:1022-1025.
31. Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 1992;15:63-68.
32. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996;11:95.
33. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12:246-248.
34. Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202.
35. McLellan DL. The suppression of involuntary movements with tetrabenazine. Scott Med J 1972;17:367-370.
36. Shoulson I, Goldblatt D. Huntington's disease (HD): effect of tetrabenazine and antipsychotic drugs on motoric features. Neurology 1981;31:79.
37. Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington's chorea. Med J Aust 1976;1:583-584.
38. Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989;4:282-287.
39. Jankovic J, Hunter C, Mejia N, Vuong K. Tetrabenazine: effective treatment for tardive dyskinesia. Mov Disord 2004;19(Suppl. 9):S73.
40. Cummings JL. What we can learn from open-label extensions of randomized clinical trials. Arch Neurol 2006;63:18-19.
41. Daniel CL, Moreland LW. Infliximab: additional safety data from an open label study. J Rheumatol 2002;29:647-649.
42. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992;1:113-119.
43. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-47.
44. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051-1054.
45. Swash M, Roberts AH, Zakko H, Heathfield KW. Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 1972;35:186-191.
46. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974;1:104-107.